News
Video
Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials
Author(s):
Drs Sholler and Agrawal detail recent studies on naxitamab and dinutuximab demonstrating effectiveness in treating recurrent or refractory neuroblastoma, leading to their FDA approvals, and significantly influencing treatment practices.
EP: 1.An Overview of Neuroblastoma
EP: 2.Approaches to Diagnosing Neuroblastoma
EP: 3.Role of CURIE Scores in the Treatment and Management of Neuroblastoma
EP: 4.Current Treatment Paradigm for Newly Diagnosed Neuroblastoma
EP: 5.Differentiating Refractory and Relapsed Neuroblastoma
EP: 6.Updated Data From the LEAHRN Study in High-Risk Neuroblastoma
EP: 7.Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)
Now Viewing
EP: 8.Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials
EP: 9.Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R
EP: 10.Future Perspectives in the Treatment of Neuroblastoma
Related Videos
Related Content
